Resmetirom is a thyroid hormone receptor agonist that has been recently approved by the FDA for the management of metabolic dysfunction-associated steatohepatitis (MASH). MASH is a severe form of metabolic dysfunction-associated fatty liver disease (MASLD), which is marked by hepatic inflammation and potential progression to cirrhosis and liver cancer. This review analyzes and demonstrates the efficacy of resmetirom in reducing intra-hepatic lipids, improving liver histology, and improving metabolic parameters. Key outcomes of this study indicate that resmetirom leads to non-alcoholic steatohepatitis (NASH) resolution and fibrosis improvement in a substantial percentage of patients. Although this drug has common gastrointestinal side effects, it maintains a favorable safety profile. With the increase in demand for treatments of MASH, the ongoing phase 3 trials will provide critical insights into the long-term efficacy and safety profile of resmetirom and further solidify its potential as a groundbreaking therapeutic option for the management of MASH.